According to The Fly, in a new note to investors today, an analyst has provided a rating update for the Healthcare company, Endo International plc (ENL). Canaccord Genuity’s analyst Dewey Steadman upgraded ENL to Buy.
According to TipRanks.com, Steadman is a 1-star analyst with an average return of -2.4% and a 34.2% success rate. Steadman covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals Inc, ANI Pharmaceuticals Inc, and Pacira Pharmaceuticals.
The the analyst consensus on Endo International plc is currently a Moderate Buy rating.
Based on Endo International plc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of C$226 million. In comparison, last year the company had a GAAP net loss of C$121 million.
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals.